14. Chronic inflammatory demyelinating polyneuropathy Clinical trials / Disease details
Clinical trials : 167 / Drugs : 158 - (DrugBank : 38) / Drug target genes : 13 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-005558-31-IT (EUCTR) | 26/01/2015 | 20/05/2015 | Extension of the international study on efficacy and safety of I10E in CIDP patients | International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM studyI10E-1302 - PRISM 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) MedDRA version: 18.0;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: : immunoglobulina umana normale 10% per somministrazione endovenosa Product Code: I10E INN or Proposed INN: immunoglobulina umana normale per somministrazione endovenosa Other descriptive name: IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa | LFB BIOTECHNOLOGIES | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 3 | France;Morocco;Mexico;Spain;Turkey;Germany;United Kingdom;Italy |